Terra Magnum Capital Partners

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.

Walking Fish Therapeutics is focused on creating cell-based therapeutics that utilize the unique capabilities of B cells to activate the immune system for cancer treatment. The company is developing a platform that aims to function as in vivo protein factories, producing replacement proteins for deficiency diseases and engineered antibodies. By harnessing the power of locally acting proteins, Walking Fish Therapeutics seeks to address serious health conditions across oncology, regenerative medicine, and autoimmune diseases, ultimately enabling healthcare providers to concentrate on innovative therapeutic approaches in these fields.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Flame Biosciences, Inc. is a clinical-stage biotechnology company based in New York, dedicated to the research, development, and commercialization of innovative therapies targeting cancer and inflammatory diseases. The company is focused on creating transformative treatments, including FL-101, which addresses lung cancers associated with inflammation, and FL-201, aimed at reducing chronic inflammation in patients. Established in 2017, Flame Biosciences seeks to improve the quality of life for individuals suffering from debilitating and life-threatening conditions through its advanced therapeutic solutions.

RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, designed for conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. In addition to inebilizumab, Viela Bio is developing VIB4920, aimed at preventing kidney transplant rejection and treating Sjögren's syndrome, and VIB7734, which targets cutaneous lupus erythematosus. The company has formed a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, Viela Bio is committed to addressing critical pathways underlying autoimmune diseases to improve patient outcomes.